Torres-Martinez Zally, Delgado Yamixa, Ferrer-Acosta Yancy, Suarez-Arroyo Ivette J, Joaquín-Ovalle Freisa M, Delinois Louis J, Griebenow Kai
Chemistry Department, University of Puerto Rico- Rio Piedras campus, San Juan, PR 00936, USA.
Biochemistry & Pharmacology Department, San Juan Bautista School of Medicine, Caguas, PR 00726, USA.
Cancer Drug Resist. 2021;4(1):163-191. doi: 10.20517/cdr.2020.64. Epub 2021 Mar 19.
Cancer cells can develop resistance to anticancer drugs, thereby becoming tolerant to treatment through different mechanisms. The biological mechanisms leading to the generation of anticancer treatment resistance include alterations in transmembrane proteins, DNA damage and repair mechanisms, alterations in target molecules, and genetic responses, among others. The most common anti-cancer drugs reported to develop resistance to cancer cells include cisplatin, doxorubicin, paclitaxel, and fluorouracil. These anticancer drugs have different mechanisms of action, and specific cancer types can be affected by different genes. The development of drug resistance is a cellular response which uses differential gene expression, to enable adaptation and survival of the cell to diverse threatening environmental agents. In this review, we briefly look at the key regulatory genes, their expression, as well as the responses and regulation of cancer cells when exposed to anticancer drugs, along with the incorporation of alternative nanocarriers as treatments to overcome anticancer drug resistance.
癌细胞能够对抗癌药物产生耐药性,从而通过不同机制对治疗产生耐受性。导致产生抗癌治疗耐药性的生物学机制包括跨膜蛋白的改变、DNA损伤和修复机制、靶分子的改变以及遗传反应等。据报道,对癌细胞产生耐药性的最常见抗癌药物包括顺铂、阿霉素、紫杉醇和氟尿嘧啶。这些抗癌药物具有不同的作用机制,特定的癌症类型可能受到不同基因的影响。耐药性的产生是一种细胞反应,它利用差异基因表达,使细胞能够适应并在各种威胁性环境因素中存活。在这篇综述中,我们简要探讨关键调控基因、它们的表达,以及癌细胞在接触抗癌药物时的反应和调控,同时纳入替代纳米载体作为克服抗癌药物耐药性的治疗方法。